Amarin Corp. plc, of Dublin, reported net revenue of $429.8 million for 2019, up 87% over 2018. Fourth-quarter net revenue totaled $143.3 million. Growth was driven primarily by sales of cardiovascular disease drug Vascepa (icosapent ethyl), prescriptions for which increased by 84% and 85% year over year, according to data from Symphony Health Solutions and Iqvia, respectively. Amarin reaffirmed previously provided guidance of 2020 net total revenue of $650 million to $700 million. For the full year, Amarin reported a GAAP net loss of $22.6 million, or 7 cents per share. As of Dec. 31, Amarin had $644.6 million in cash and equivalents. Company shares (NASDAQ:AMRN) closed Feb. 26 at $16.27, down $1.23.
Jazz Pharmaceuticals plc, of Dublin, reported total revenue of $2.2 billion for 2019, up 14% over the prior year. 2019 GAAP net income was $523.4 million and diluted earnings per share (EPS) was $9.09. For the fourth quarter, revenue totaled $581.7 million, and GAAP net come totaled $74 million, with diluted EPS of $1.29. Sales of narcolepsy drug Xyrem (sodium oxybate) oral solution reached $1.6 billion and $435 million for the year and quarter, respectively, while leukemia drug Erwinaze/Erwinase (asparaginase Erwinia chrysanthemi) had sales of $177.5 million and $55 million and veno-occlusive disease drug Defitelio (defibrotide sodium) had sales of $172.9 million and $47.8 million, respectively. Sales of acute myeloma leukemia drug Vyxeos (daunorubicin and cytarabine) liposome for injection reached $121.4 million and $31.5 million, respectively, while recently launched Sunosi (solriamfetol), cleared for excessive daytime sleepiness in patients with narcolepsy or sleep apnea, posted sales of $2.7 million for its first full quarter on the market. As of Dec. 31, Jazz had cash, cash equivalents and investments totaling $1.1 billion. The company’s shares (NASDAQ:JAZZ) closed Feb. 26 at $116.59, down $10.66.
United Therapeutics Corp., of Silver Spring, Md., reported 2019 net revenue of $1.449 billion, a decrease of 11% from the prior year, which the company attributed largely to the launch of generic versions of its pulmonary arterial hypertension (PAH) drug Adcirca (tadalafil tablets). For the fourth quarter, net revenue totaled $311 million, down 18% over the fourth quarter of 2018. The company posted a net loss of $104.5 million, or $2.39 per basic share, for the full year and a net income of $52.6 million, or $1.20 per basic share, for the fourth quarter. In its treprostinil PAH franchise, sales of Remodulin were $587 million and $107.4 million, sales of Tyvaso were $415.6 million and $91.4 million and sales of Orenitram were $225.3 million and $50.9 million for the full year and fourth quarter, respectively. Sales of neuroblastoma drug Unituxin (dinutuximab) reached $113.7 million and $33.6 million, respectively. As of Dec. 31, United had about $2.25 billion on its balance sheet. The company’s shares (NASDAQ:UTHR) closed Feb. 26 at $105.81, down $7.05.
Vanda Pharmaceuticals Inc., of Washington, posted full-year 2019 revenues of $227.2 million, up 18% over the prior year. Fourth-quarter revenues were $60.9 million, up 15% over the prior year. Sales of sleep-wake disorder drug Hetlioz (tasimelteon) totaled $143 million and $38.6 million for the full year and fourth quarter, respectively, while sales of schizophrenia drug Fanapt (iloperidone) were $84.2 million and $22.3 million, respectively. The company is projecting full-year 2020 revenues to fall between $240 million and $260 million. As of Dec. 31, its cash, equivalents and marketable securities were $312.1 million.